David L. Nathan Joins Cannabis Science and Technology’s Editorial Advisory Board
Cannabis Science and Technology is pleased to announce the addition of David L. Nathan MD, DFAPA to its editorial advisory board (EAB).
Cannabis Science and Technology is pleased to announce the addition of David L. Nathan MD, DFAPA to its editorial advisory board (EAB).
Located in Princeton, New Jersey, Dr. Nathan is a psychiatrist, writer, speaker, educator, and consultant. Among his many talents, Dr. Nathan founded Doctors for Cannabis Regulation (DFCR), where he also holds the title of board president. He is also a founding steering committee member of New Jersey United for Marijuana Reform. In 2019, Dr. Nathan was one of two physicians to testify at the first United States House Judiciary Committee hearing regarding cannabis legislation.
Dr. Nathan graduated magna cum laude from Princeton University and he received his MD from the University of Pennsylvania School of Medicine. He then went on to complete his psychiatry residency at McLean Hospital of Harvard Medical School. Dr. Nathan is a Distinguished Fellow of the American Psychiatric Association, Clinical Associate Professor of Psychiatry at Rutgers Robert Wood Johnson Medical School, and a community fellow at Mathey College of Princeton University.
Dr. Nathan has written and spoken extensively on cannabis policy, with audiences ranging from lawmakers, businesspeople, state medical societies, hospital medical staff, allied health professionals, and the lay public. He has testified before eight state legislatures and the U.S. Congress, and he coauthored a landmark article on cannabis regulation with former Surgeon General Joycelyn Elders for the American Journal of Public Health.
Dr. Nathan has appeared in nationally syndicated broadcast, online and print media publications, with more prominent outlets including CNN, The New York Times, Wall Street Journal, Washington Post, US News & World Report, VICE News, San Francisco Chronicle, Politico, The Week (UK), and SinoVision News. He has also appeared in many state, province, and local media outlets around the United States and Canada.
Dr. Nathan serves as a cannabis consultant for government and industry. He is currently the Chief Medical Advisor for 4Front Ventures, a multistate medical cannabis company.
During his free time, Dr. Nathan publishes articles on a variety of historical subjects such as early written language, numismatics, animation, and the dawn of American football.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
